Potassium Channel Blockers
Delaying the reset. How stretching out the refractory shield shuts down reentry circuits from within.
We have slowed conduction (Class I) and cut the sympathetic drive (Class II). Now, we attack the recovery phase. We delay the reset. By blocking potassium, we keep the cell depolarized longer. We stretch out the shield.
Reentry relies on timing. A short-circuit only survives if it can continuously find recovered tissue to burn. If the tissue stays in its refractory state just a fraction of a second longer, the circuit hits a wall.
This is the elegant promise of Class III antiarrhythmics. We do not stop the initial spark; we simply make the tissue unburnable for longer.
Plugging the Exit Doors
As we established in Volume I, Phase 3 of the action potential is the great repolarization. It is driven by massive quantities of potassium rushing out of the cell, dropping the internal voltage back down to its resting negative state.
Two major currents carry this outward flow: IKr (rapid) and IKs (slow). They are the heavy exit doors of the cellular battery.
Class III drugs—like Amiodarone, Sotalol, and Dofetilide—are highly specific doorstops. They physically plug the IKr and IKs channels. With the exit doors blocked, potassium struggles to leave. The cell remains positively charged, trapped in its plateau and early repolarization phase.
Stretching the Shield
Because repolarization is agonizingly slow, the total Action Potential Duration (APD) physically lengthens.
For the entire duration of this prolonged Phase 3, the cell sits in its absolute refractory period. It cannot be stimulated again, no matter how hard an incoming electrical wave tries. The shield is up.
When you zoom out from the single cell to the surface ECG, this delayed repolarization has a very obvious signature. The T wave comes later. The QT interval stretches.
Closing the Excitable Gap
In Volume III, we defined reentry as a wave eternally chasing its own tail. Between the tail of refractory tissue and the advancing head of the wavefront, there is a physical distance of fully recovered, ready-to-burn tissue. This is the excitable gap.
Class III drugs shrink this gap.
By lengthening the action potential duration, they draw out the tail. The refractory tissue stretches further and further back, eating up the excitable gap. Eventually, the wavefront catches up to its own unrecovered tail. The circuit crashes into refractory tissue and extinguishes itself. The rhythm terminates.
Reverse Use-Dependence
There is a dark side to this mechanism. The laws of biophysics demand a trade-off.
Sodium channel blockers (Class I) exhibit use-dependence. They block stronger when the heart rate is fast, stepping up exactly when you need them during a rapid tachycardia.
Potassium channel blockers typically exhibit reverse use-dependence. At very fast heart rates, there is less time for the drug to bind to the potassium channels. The blocking effect weakens. But when the heart rate slows down—say, to 50 beats per minute during sleep—the drug binds heavily. The action potential duration skyrockets. The QT interval stretches dangerously long.
The Perfect Storm for Torsades
This excessive prolongation is a setup for disaster. As we discussed in Volume III, stretching the plateau phase invites calcium channels to mistakenly reopen. This triggers Early Afterdepolarizations (EADs).
If an EAD is large enough, it fires a premature beat right on top of the stretched-out T wave. The result is Torsades de Pointes—a twisting, chaotic ventricular tachycardia that can quickly degenerate into ventricular fibrillation.
This is why initiating drugs like Sotalol or Dofetilide requires in-hospital monitoring. We must watch the QT interval stretch, ensuring it stops before it reaches the breaking point.
Amiodarone is officially classified as a Class III drug, but it is actually the ultimate "dirty" drug. It possesses Class I (sodium), Class II (beta), Class III (potassium), and Class IV (calcium) blocking properties. It suppresses everything.
This broad-spectrum blockade makes it incredibly effective at terminating almost any arrhythmia, and uniquely, it does not exhibit reverse use-dependence, meaning its risk of triggering Torsades is shockingly low compared to other Class III agents.
However, there is a heavy price. Its massive, iodine-heavy molecular structure is highly lipophilic. Over years of use, it accumulates in fat, creating catastrophic toxicity in the thyroid, lungs, and liver. It is an unmatched weapon, but it poisons the well over time.
Key Takeaways
- The Target: Class III drugs block the outward IKr and IKs potassium currents that normally drive Phase 3 repolarization.
- The Consequence: Delaying repolarization significantly lengthens the Action Potential Duration (APD) and prolongs the absolute refractory period.
- The Termination: By stretching the refractory tissue, these drugs close the "excitable gap," forcing reentry circuits to crash into their own unrecovered tails.
- The Flaw: Most potassium blockers exhibit reverse use-dependence, meaning they excessively prolong the QT interval at slow heart rates, risking Early Afterdepolarizations (EADs) and Torsades de Pointes.
- The King: Amiodarone is highly effective due to its multi-channel (dirty) blockade, but its heavy iodine structure causes severe long-term organ toxicity.